Research and Development - The company reported a strong focus on research and development, with industry-leading investment in R&D and product innovation capabilities [8]. - Research and development expenses accounted for over 15% of total sales revenue, highlighting the company's commitment to innovation [28]. - The group reported a total R&D expenditure of approximately RMB 4,454.18 million, representing about 15.5% of the group's revenue, with over 74% of this investment allocated to innovative and biological drugs [64]. - The company has 40 innovative drug candidates in the oncology field at clinical application stages, with 8 expected to be approved for market in the next three years (2023-2025) [40]. - The company has 8 innovative drug candidates in the liver disease field, with 4 expected to be approved for market in the next three years (2023-2025) [41]. - The company has 10 innovative drug candidates in the respiratory system field at clinical application stage or above, including 1 in the market application stage and 5 in Phase II clinical trials [45]. - The company is conducting Phase II clinical trials for TDI01, a selective ROCK2 inhibitor, targeting conditions such as pneumoconiosis and COVID-19 [46]. - The company has submitted a market application for Enzastaurin, a new oral COVID-19 treatment, which shows significant improvement in symptoms associated with the Omicron variant [45]. - The company plans to launch several innovative drug products in the next three years, including TQB2450 and TQ-B3101, which are currently in the application stage [33]. Financial Performance - Revenue for 2022 reached RMB 28,780,412 thousand, an increase from RMB 26,861,356 thousand in 2021, representing a growth of approximately 7.1% [25]. - Gross profit for 2022 was RMB 22,984,902 thousand, compared to RMB 21,529,261 thousand in 2021, indicating a year-over-year increase of about 6.8% [25]. - The net profit for 2022 was RMB 5,002,618 thousand, a decrease from RMB 16,614,793 thousand in 2021, representing a decline of approximately 69.9% [25]. - The company reported a pre-tax profit of RMB 5,778,604 thousand for 2022, down from RMB 18,572,673 thousand in 2021, indicating a decline of approximately 68.9% [25]. - Profit attributable to equity holders decreased by approximately 82.6% to RMB 2,543.57 million, with earnings per share of RMB 0.1366, down about 82.4% [50]. - Adjusted net profit under non-HKFRS was approximately RMB 2,986.33 million, an increase of about 16.4% compared to the previous year [50]. - The company’s total liabilities increased to RMB 26,120,736 thousand in 2022 from RMB 22,814,314 thousand in 2021, marking an increase of about 14.0% [25]. - The total assets of the company increased to RMB 64,064,284 thousand in 2022, up from RMB 60,543,337 thousand in 2021, reflecting a growth of approximately 4.2% [25]. Market Position and Recognition - The company has been recognized as a leading innovative pharmaceutical group in China, with a comprehensive product portfolio covering oncology, liver disease, and respiratory diseases [8]. - The company was included in the MSCI Global Standard Index as a constituent stock of the China Index, effective May 31, 2013 [11]. - The company has been listed among the "Top 50 Global Pharmaceutical Companies" for four consecutive years from 2019 to 2022 [14]. - The company successfully bid for 9 products in the national procurement process, the highest number among listed pharmaceutical companies [38]. Corporate Governance and ESG Initiatives - The company has established an ESG vision focused on high-quality management to support the United Nations Sustainable Development Goals and the Healthy China strategy [73]. - The company received awards for being one of the "Best ESG Employers" in China in 2022, highlighting its commitment to ESG principles [73]. - The board of directors is focused on overall corporate strategy and financial performance, ensuring sustainable development aligned with the company's mission [76]. - The company has implemented a strategic planning process to identify and assess risks and opportunities, aiming to create long-term value for shareholders [78]. - The company has established an ESG committee under the board to oversee significant ESG-related matters and ensure the implementation of ESG strategies [71]. Employee and Management Structure - The group had approximately 26,272 employees as of December 31, 2022 [69]. - Employee costs, including director remuneration and equity-settled share-based payment expenses, totaled approximately RMB 4,750.93 million for the year, compared to RMB 4,568.98 million in the previous year, representing an increase of about 4.0% [69]. - The company emphasizes employee development through competitive compensation, performance assessments, and training opportunities [144]. - The leadership team has received multiple awards and recognitions for their contributions to the industry and society [170][172]. Strategic Initiatives and Future Outlook - The company aims to achieve a revenue target of HKD 100 billion by 2030, driven by the launch of over ten innovative drug products in the next three years and more than forty innovative drugs expected to be launched by 2030 [51]. - The company is actively pursuing market expansion and new strategies to enhance its competitive position in the pharmaceutical industry [35]. - The company is committed to developing new drugs and modern healthcare products for cardiovascular and respiratory diseases [164]. - The company is positioned for market expansion, leveraging the expertise of its board and management team [181].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） 網站：www.sinobiopharm.com （股票編號：1177） 截至二零二二年十二月三十一日止年度之業績公告 財務摘要 十二月三十一日止年度 二零二二年 二零二一年 變動 人民幣億元 人民幣億元 % 收入 287.8 268.6 +7.1% 毛利 229.8 215.3 +6.8% 本年度盈利 50.0 166.1 -69.9% 歸屬於母公司持有者盈利（附註1） 25.4 146.1 -82.6% ...

Financial Performance - Revenue for the six months ended June 30, 2022, was RMB 15.19 billion, an increase of 5.9% from RMB 14.35 billion in 2021[9] - Gross profit for the same period was RMB 12.23 billion, reflecting a 5.5% increase from RMB 11.60 billion in the previous year[9] - Profit attributable to owners of the parent decreased by 77.3% to RMB 1.92 billion from RMB 8.48 billion in 2021[9] - Adjusted net profit attributable to owners of the parent was RMB 1.66 billion, up 4.5% from RMB 1.59 billion in the prior year[9] - Total comprehensive income for the period was RMB 2,575,491, significantly lower than RMB 9,905,092 in the prior year[51] - The company reported a net profit of RMB 3,183,221 for the six months ended June 30, 2022, compared to RMB 9,641,604 for the same period in 2021, indicating a significant decrease[63] - The profit from equity investments at fair value through profit or loss was RMB 154,199,000 for the first half of 2022, compared to a loss of RMB 19,618,000 in the same period of 2021, indicating a significant turnaround[72] - The profit attributable to equity holders of the parent company for the six months ended June 30, 2022, was RMB 1,921,037,000, a decrease of 77.3% compared to RMB 8,480,340,000 for the same period in 2021[78] Revenue Breakdown - Revenue from new products reached RMB 6.61 billion, representing a 24.6% increase and accounting for 43.5% of total revenue[9] - Revenue from anti-tumor drugs was RMB 4.96 billion, a 16.7% increase, making up 32.6% of total revenue[9] - Revenue from innovative drugs was RMB 3.49 billion, up 14.2%, contributing 22.9% to total revenue[9] - Sales revenue from new products increased from approximately 36.9% to 43.5% of total revenue[25] - Revenue from surgical/pain relief drugs was approximately RMB 252,050 million, accounting for about 16.6% of total revenue, with a growth of about 7.1% year-on-year[26] - Revenue from liver disease drugs was approximately RMB 200,891 million, accounting for about 13.2% of total revenue, with a growth of about 11.1% year-on-year[27] - Revenue from cardiovascular drugs was approximately RMB 155,220 million, accounting for about 10.2% of total revenue, with a growth of about 13.8% year-on-year[29] Research and Development - The company emphasizes R&D and innovation, maintaining industry-leading investment in R&D and product innovation capabilities[12] - The group has a total of 418 products under research and development, including 230 oncology drugs and 29 liver disease drugs, as of June 30, 2022[35] - Research and development expenses for the six months ended June 30, 2022, totaled approximately RMB 2,191.59 million, representing 14.4% of the group's revenue, compared to 13.1% in the previous year[35] - Research and development costs for the period were RMB 2,048,604, compared to RMB 1,781,597 in the same period last year, indicating a focus on innovation[50] - The company is focusing on high-innovation and high-market-potential products in its pipeline, reassessing its R&D investments in light of the potential impacts of national procurement policies on generic drugs[47] Market and Economic Context - In the first half of 2022, China's GDP reached RMB 56.3 trillion, with a year-on-year growth of 2.5%[18] - The pharmaceutical manufacturing industry's revenue growth in Q1 2022 was lower than GDP growth, primarily due to the high base from the previous year and ongoing pandemic impacts[18] - In Q2 2022, the severe pandemic affected medical service volumes and pharmaceutical consumption, leading to a decline in healthcare expenditure and consumer income levels[18] Corporate Governance and ESG - The company has committed to a comprehensive ESG governance strategy, focusing on disease treatment, pharmaceutical accessibility, environmental friendliness, and win-win relationships[44] - The company has initiated the construction of an ESG digital platform, expected to be fully operational by Q4 2022, to improve ESG management through data visualization and performance tracking[45] - The company has not experienced any significant ESG-related risk incidents in the first half of 2022, indicating effective risk management practices[45] - The company held six monthly ESG management committee meetings in the first half of 2022, ensuring over 75% attendance from committee members[45] Shareholder Information - As of June 30, 2022, the company had a total issued share capital of 18,800,000,000 shares[100] - Ms. Xie Qirun holds 2,279,254,761 shares, representing approximately 12.11% of the total issued share capital[101] - Mr. Xie Chengrun holds 4,050,000,000 shares, accounting for 21.53% of the total issued share capital[101] - The company has a stock option plan approved on May 28, 2013, allowing for the issuance of shares not exceeding 10% of the total issued share capital at the time of adoption[107] - The company’s stock option grants to major shareholders require prior approval from independent non-executive directors[107] Cash Flow and Liquidity - The net cash flow from operating activities for the six months ended June 30, 2022, was RMB 3,948,941, compared to RMB 2,335,554 for the same period in 2021, representing a significant increase[57] - Cash and bank balances decreased to RMB 7,768,292 from RMB 10,568,812 at the end of 2021, reflecting liquidity challenges[52] - The company experienced a net decrease in cash and cash equivalents of RMB (3,501,245) for the first half of 2022, compared to RMB (2,482,102) in the same period of 2021[57] Investment and Capital Expenditure - The company issued €750 million zero-coupon convertible bonds due in 2025, with net proceeds allocated for R&D, production facilities, sales, and general corporate purposes[111] - The group had capital commitments of RMB 1,717,675,000 as of June 30, 2022, compared to RMB 910,967,000 as of December 31, 2021, reflecting an increase of 88.8%[84] - Capital expenditure for the six months ended June 30, 2022, was RMB 789,555, compared to RMB 566,721 in the same period of 2021, showing an increase of approximately 39.3%[63]

Financial Performance - Revenue for 2021 was RMB 26.9 billion, with a net profit of RMB 16.6 billion[15]. - The company's revenue for the year 2021 reached RMB 26,861,356 thousand, an increase from RMB 23,647,224 thousand in 2020, representing a growth of approximately 9.4%[31]. - Gross profit for 2021 was RMB 21,529,261 thousand, compared to RMB 18,464,904 thousand in 2020, indicating a growth of about 16.4%[31]. - The operating profit for 2021 was RMB 5,112,091 thousand, showing an increase from RMB 4,527,582 thousand in 2020, which is a growth of approximately 12.9%[32]. - The net profit attributable to equity holders of the parent company for 2021 was RMB 14,608,412 thousand, significantly higher than RMB 2,771,086 thousand in 2020, marking an increase of approximately 426.5%[31]. - The net profit attributable to equity holders for the year was RMB 16,614,793,000, significantly up from RMB 4,340,667,000 in 2020, reflecting a year-over-year increase of approximately 284%[113]. - The company reported a significant increase in other income and profits, totaling RMB 1,068,929 thousand in 2021, compared to RMB 1,241,223 thousand in 2020[31]. - The company achieved a total revenue of approximately RMB 26.86 billion in the fiscal year, representing a year-on-year growth of about 13.6%[50]. - The basic earnings per share for the year ended December 31, 2021, was RMB 15.62, an increase from RMB 12.31 in the previous year[59]. Research and Development - The company has a strong focus on R&D, with industry-leading investment and innovation capabilities[6]. - Research and development expenses accounted for over 14% of total sales revenue, highlighting the company's commitment to innovation[33]. - The company is investing heavily in R&D, with a projected budget increase of 15% for the upcoming fiscal year[37]. - The total R&D expenditure for the year was approximately RMB 3,820.17 million, representing about 14.2% of the group's revenue, with a year-on-year increase of approximately 64.7% in investment for innovative drugs and biopharmaceuticals[65]. - The company obtained 36 new product approvals and submitted 52 clinical applications, including 26 for innovative drugs in 2021[49]. - The company plans to enhance its R&D innovation strategy and focus on unmet clinical needs in oncology, liver disease, and cardiovascular areas[51]. Market Expansion and Strategy - The company is actively expanding its market presence and leveraging big data and artificial intelligence to enhance operational efficiency[6]. - The company aims to expand its market presence significantly, focusing on both domestic and international markets[39]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[28]. - The company has identified strategic acquisition opportunities to enhance its product portfolio and market reach[39]. - The company plans to launch 20 new products in the respiratory system and musculoskeletal fields over the next three years, including HBQ and LM[37]. - The revenue from the respiratory system segment reached RMB 22.42 billion in 2021, showing a substantial growth compared to previous years[34]. Corporate Governance - The company has established various committees, including the Audit Committee, Remuneration Committee, and Nomination Committee, to oversee governance and compliance[86]. - The board consists of nine executive directors, including the chairperson and CEO, and five independent directors[79]. - Independent directors account for more than one-third of the board, providing valuable independent perspectives and advice[80]. - The board meets at least four times a year, with additional special meetings as necessary[78]. - The chairperson and CEO roles are separated, with the chairperson overseeing board operations and the CEO managing the group's business[82]. - The board is responsible for reviewing and monitoring compliance with legal and regulatory requirements[81]. Social Responsibility and Community Engagement - The company donated RMB 5 million and emergency relief materials worth RMB 5 million to support disaster relief efforts in Henan Province[48]. - The group actively engages in community investment and corporate social responsibility initiatives, including pandemic response and educational donations[73]. - The company is committed to providing a healthy and safe working environment for employees through various activities, including health checks and safety management[121]. - The company has implemented environmental protection measures, including energy conservation and waste reduction, to enhance its environmental performance[120]. Financial Position and Assets - The total assets of the company as of 2021 were RMB 60,543,337 thousand, up from RMB 47,210,438 thousand in 2020, reflecting a growth of about 28.5%[31]. - The total liabilities decreased to RMB 22,814,314 thousand in 2021 from RMB 24,790,880 thousand in 2020, indicating a reduction of about 7.9%[31]. - The company reported a net asset value of RMB 40 billion in 2021, with cash and bank balances amounting to RMB 37.73 billion[34]. - The company’s total reserves increased to RMB 30,565,023,000 by the end of 2021, up from RMB 16,801,209,000 at the end of 2020, reflecting a growth of approximately 82%[173]. Shareholder Information - The company proposed a final dividend of HKD 0.04 per share for the year ended December 31, 2021, subject to shareholder approval[110]. - The company maintains a consistent policy of providing stable and sustainable dividends, dependent on financial performance and cash flow[108]. - The top five customers accounted for less than 30% of total sales, indicating a diversified customer base[119]. Compliance and Risk Management - The company adheres to relevant Chinese laws and regulations regarding drug research and development, production, and distribution, ensuring compliance without significant violations[122]. - The group has established a risk compliance committee to enforce risk management protocols and ensure comprehensive risk assessment and control[73]. - The company is closely monitoring foreign exchange net risks to mitigate the impact of currency fluctuations on its assets and liabilities[72]. Leadership and Management - The company has a strong leadership team with extensive experience in management and investment in the pharmaceutical sector[143]. - The Chief Financial Officer, Ms. Ma Jiayin, holds an MBA from Columbia Business School and has over 20 years of financial management experience[151]. - The company appointed Professor Mao Li as Chief Medical Officer, bringing 35 years of oncology clinical practice and research experience[151]. - The company has a diverse board with members who have significant academic and professional backgrounds in finance, management, and pharmaceuticals, enhancing its strategic decision-making capabilities[148].

Financial Performance - Revenue for 2020 was RMB 23.6 billion, with a net profit of RMB 4.3 billion[36] - The company's revenue for 2020 was RMB 23,647,224 thousand, with a gross profit of RMB 18,464,904 thousand, reflecting a gross margin of approximately 78%[40] - The net profit for 2020 was RMB 4,340,667 thousand, a decrease from RMB 4,787,845 thousand in 2019[40] - The total revenue for 2020 was approximately RMB 23,647.22 million, a slight decrease of about 2.4% compared to the previous year[70] - Profit attributable to equity holders of the parent company was approximately RMB 2,771.09 million, a slight increase of about 0.3% year-on-year[70] - Gross profit for 2020 was RMB 18,464,904, compared to RMB 19,307,762 in 2019, reflecting a decline of 4.4%[143] - Total assets increased to RMB 47,134,653 in 2020, up from RMB 37,514,192 in 2019, representing a growth of 25.0%[143] - Total liabilities rose to RMB 24,788,069 in 2020, compared to RMB 16,953,010 in 2019, marking an increase of 46.5%[143] Research and Development - The company emphasizes R&D and innovation, with industry-leading R&D investment and product innovation capabilities[30] - Research and development expenses accounted for over 12% of total sales revenue, indicating a strong commitment to innovation[43] - The company’s R&D spending has been consistently increasing, reflecting its strategy to enhance product offerings and market competitiveness[43] - Total R&D expenditure for the year ended December 31, 2020, was approximately RMB 2,852.68 million, accounting for about 12.1% of the company's revenue[86] - The company has a strong product pipeline with 191 patent grants, including 158 invention patents, maintaining a leading position among domestic pharmaceutical companies[69] Product Development and Launches - The company plans to launch 20 new products in 2021, including several oncology and orthopedic drugs that have already received approval[48] - The company plans to launch 28 new products in 2023, focusing on areas such as oncology, diabetes, and respiratory health[54] - The new product pipeline includes TQB3525, a liposomal formulation for anti-infection, and multiple oncology drugs like patritumab and aflibercept[54] - The sales revenue from new products accounted for approximately 38.1% of total revenue, up from about 20.7% in the previous year[70] - The new respiratory product Tianqing Suchang generated over RMB 500 million in revenue within six months of its launch[1] Market Presence and Strategy - The company has a significant presence in the pharmaceutical market, with a focus on both research and distribution across various therapeutic areas[43] - The company has a nationwide sales network with over 13,000 sales personnel, covering more than 90% of hospitals in China[43] - The company is actively pursuing mergers and acquisitions to enhance its product portfolio and market reach[54] - The anticipated revenue growth from new product launches is projected to contribute significantly to the overall financial performance in the upcoming fiscal year[54] - The company is entering a rapid development phase in internet healthcare, supported by national policies, which is transforming pharmaceutical marketing towards online models[61] Corporate Governance - The board of directors consists of nine executive directors, including the chairperson and CEO, and five independent non-executive directors[103] - The company has established various committees, including the Executive Committee, Audit Committee, Remuneration Committee, and Nomination Committee, to enhance board efficiency and encourage active participation[99] - The company has complied with all provisions of the Corporate Governance Code, except for specific attendance issues at the annual general meeting[98] - The board is responsible for overall corporate strategy and policy, focusing on the group's development and financial performance[99] - The company maintains high levels of corporate governance to ensure sustainable development, actively engaging with local and overseas investors[86] Shareholder Engagement and Dividends - A total of approximately HKD 1,006,318,000 (equivalent to approximately RMB 894,944,000) in dividends was distributed for the year 2020, with a proposed final dividend of HKD 0.02 per share[139] - The company maintains a policy of providing stable and sustainable dividends, dependent on financial performance, cash flow, and future capital needs[135] - The company has established a comprehensive policy for communication with shareholders, ensuring high standards of disclosure and financial transparency[133] - The board of directors attended the 2020 annual general meeting to respond to shareholder inquiries, with all resolutions passed by a poll vote[133] Operational Efficiency and Sustainability - The company is committed to enhancing its operational efficiency through strategic partnerships and collaborations in the pharmaceutical industry[54] - The company is focused on sustainability initiatives, aiming for a 30% reduction in carbon footprint by 2025[197] - The management team emphasized the importance of improving operational efficiency, aiming for a 5% reduction in costs over the next year[194] - The company is committed to environmental protection and has implemented measures to reduce energy consumption and waste during production[152] Awards and Recognition - The company has been recognized in the "Top 50 Best Companies in Asia-Pacific" by Forbes for three consecutive years from 2016 to 2018[33] - The company’s product, Kena (Bepotastine Besilate Tablets), won the "Outstanding Product Brand in Blood and Hematopoietic System" award in 2020, showcasing its innovation in the pharmaceutical sector[65] - The company has been included in the "Top 50 Global Pharmaceutical Companies" list by Pharm Exec for two consecutive years in 2019 and 2020[183] - The company has been recognized for its contributions to the development of the Chinese pharmaceutical industry, receiving multiple personal honors for its leadership[185] Employee and Management - The company has a total of 24,108 employees, including directors, as of December 31, 2020[173] - The company has a strong leadership team with extensive experience in the pharmaceutical industry, including executives with backgrounds in finance and management from prestigious institutions[187][189][191] - The company has a strong emphasis on employee welfare and has been recognized as an outstanding employer in its region[187]

Financial Performance - The company reported revenue of approximately RMB 12,647.78 million for the six months ended June 30, 2020, representing a year-on-year growth of about 1.0%[11]. - Profit attributable to equity holders of the parent was approximately RMB 1,213.08 million, a decrease of about 16.0% compared to the same period last year[11]. - Basic earnings per share attributable to equity holders of the parent was approximately RMB 0.0964, down approximately 16.0% year-on-year[11]. - The company recorded revenue of approximately RMB 1,264,778 million, representing a year-on-year growth of about 1.0%[22]. - The group recorded a net profit attributable to the parent company of RMB 2,016,327 thousand, a decrease of 7.65% from RMB 2,183,801 thousand in the previous year[45]. - The company’s total comprehensive income for the period was RMB 2,067,157 thousand, compared to RMB 2,180,253 thousand in 2019, reflecting a decline of 5.19%[45]. - The group reported a revenue of RMB 12,647,775 thousand for the six months ended June 30, 2020, representing a slight increase of 0.96% compared to RMB 12,527,309 thousand in the same period of 2019[43]. - The group’s basic earnings per share for the period was RMB 0.096, compared to RMB 0.115 for the same period in 2019, indicating a decrease of about 16%[69]. Product and Market Development - Sales from new products accounted for approximately 34.8% of the total revenue[11]. - The sales of oncology drugs reached approximately RMB 401,756 million, accounting for about 31.8% of the company's total revenue[23]. - The sales of the new product Anxian (lenalidomide capsules) grew by approximately 69.3% to RMB 16,443 million[24]. - The sales of respiratory system drugs amounted to approximately RMB 59,732 million, representing about 4.7% of total revenue[27]. - The sales of liver disease drugs were approximately RMB 224,864 million, accounting for 17.8% of total revenue[23]. - The company has a diverse product portfolio covering various therapeutic areas, including liver disease, oncology, orthopedics, and respiratory diseases[13]. Research and Development - The company emphasizes R&D and innovation, with industry-leading investment in R&D and product innovation capabilities[13]. - Research and development expenses totaled approximately RMB 154,057,000, accounting for 12.2% of the group's revenue[33]. - The group had a total of 438 products in clinical trials or under production application, including 189 oncology drugs and 38 liver disease drugs[32]. - The company submitted 263 new patent applications during the review period, with 82 invention patents granted[22]. - The group reported research and development expenses of RMB 1,540,569,000 for the first half of 2020, down from RMB 1,625,550,000 in 2019, indicating a reduction of approximately 5%[64]. Financial Position and Cash Flow - As of June 30, 2020, cash and bank balances were approximately RMB 17,090.76 million[11]. - The group reported cash and bank balances of RMB 17,090,761,000 as of June 30, 2020, compared to RMB 11,911,210,000 at the end of 2019, showing an increase of about 43%[72]. - The total assets of the group were approximately RMB 6,834,834,000, up from RMB 5,829,925,000 at the end of 2019, representing a growth of 17.2%[37]. - The total liabilities increased to approximately RMB 2,684,549,000, resulting in a debt-to-asset ratio of 39.3%, compared to 30.9% at the end of 2019[37]. - The company reported a net cash flow from operating activities of RMB 1,555,549 thousand for the six months ended June 30, 2020, compared to RMB 3,507,412 thousand in the same period of 2019, indicating a decrease of approximately 55.6%[49]. - The total cash and cash equivalents at the end of the period reached RMB 15,666,602 thousand, up from RMB 6,328,584 thousand at the end of June 2019, representing an increase of approximately 148.5%[49]. Shareholder Information and Corporate Governance - The company has a stock option plan approved on May 28, 2013, allowing for the issuance of up to 494,146,147 shares, which is 10% of the issued share capital at the time[86]. - The board of directors consists of nine executive directors and four independent non-executive directors as of the report date[99]. - The company maintained high transparency during the COVID-19 pandemic by conducting a conference call that attracted over 490 analysts and fund managers to discuss the 2019 annual results and business developments[89]. - The company has complied with the Corporate Governance Code during the six months ending June 30, 2020, with a board comprising four independent non-executive directors, two of whom have financial management experience[93]. - The company repurchased 6,553,000 shares at a total cost of HKD 66,585,880 during the period ending June 30, 2020[97]. Market Recognition and Rankings - The company ranked 133rd in the list of China's top 500 listed companies, improving by 87 positions from the previous year[19]. - The company was recognized as one of the top 10 best listed biopharmaceutical companies in China for 2019[20]. - The company was included in the newly launched Hang Seng Shenzhen-Hong Kong Stock Connect Biotechnology 50 Index, ranking second among the top 10 constituent stocks[20]. - The company achieved a revenue of $3.373 billion, ranking 42nd in the global pharmaceutical companies list[20].